Transfusion Medicine Reviews
Volume 24, Issue 1 , Pages 53-63 , January 2010

Albumin Usage in Clinical Medicine: Tradition or Therapeutic?

  • Albert Farrugia

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Albert Farrugia, Plasma Protein Therapeutics Association, 147 Old Solomon's Island Rd. Annapolis, MD 21401.

References 

  1. Quinlan GJ, Martin GS, Evans TW. Albumin: Biochemical properties and therapeutic potential. Hepatology. 2005;41:1211–1219
  2. Burnouf T. Plasma proteins: Unique biopharmaceuticals - unique economics. In:  Valverde JL editors. Blood, plasma and plasma proteins: A unique contribution to modern healthcare. Pharmaceutical Policy and Law 2005. 7:2006;p. 209–218
  3. Foley EF, Borlase BC, Dzik WH, et al. Albumin supplementation in the critically ill. Arch Surg. 1990;125:739–742
  4. Boldt J, Heesen M, Müller M, et al. The effects of albumin versus hydroxyethyl starch solution on cardiorespiratory and circulatory variables in critically III patients. Anesth Analg. 1996;83:254–261
  5. Van der Linden P, Ickx BE. The effects of colloid solutions on hemostasis. Can J Anesth. 2006;53(6 Suppl):S30–S39
  6. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: Systematic review of randomised controlled trials. BMJ. 1998;317:235–240
  7. Available on http://www.bmj.com/cgi/eletters/317/7153/235.
  8. Wilkes MM, Navickis RJ. Patient survival after human albumin administration: A meta-analysis of randomized, controlled trials. Ann Intern Med. 2001;135:149–164
  9. Vincent JL, Wilkes MM, Navickis RJ. Safety of human albumin: Serious adverse events reported worldwide in 1998-2000. Br J Anaesth. 2003;91:625–630
  10. Finfer S, Bellomo R, Boyce N, et al. A comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med. 2004;350:2247–2256
  11. Schortgen F, Deye N, Brochard L. Preferred plasma volume expanders for critically ill patients: Results of an international survey. Intensive Care Med. 2004;30:2222–2229
  12. In:  Curling J editors. Methods of plasma protein fractionation. Academic Press; 1980;
  13. Matejtschuk P, Dash CH, Gascoigne EW. Production of human albumin solution: A continually developing colloid. Br J Anaesth. 2000;85:887–895
  14. Che Y, Wilson FJ, Bertolini J, et al. Impact of manufacturing improvements on clinical safety of albumin: Australian pharmacovigilance data for 1988-2005. Crit Care Resusc. 2006;8:334–338
  15. Tsai MH, Huang YC, Yen MH, et al. Clinical responses of patients with Kawasaki disease to different brands of intravenous immunoglobulin. J Pediatr. 2006;48:38–43
  16. Laub R, Di Giambattista M, Fondu P, et al. Inhibitors in German hemophilia A patients treated with a double virus inactivated factor VIII concentrate bind to the C2 domain of FVIII light chain. Thromb Haemost. 1999;81:39–44
  17. Köhler M. Thrombogenicity of prothrombin complex concentrates. Thromb Res. 1999;95(4 Suppl 1):S13–S17
  18. Woodcock J, Griffin J, Behrman R, et al. The FDA's assessment of follow-on protein products: A historical perspective. Nat Rev Drug Discov. 2007;6:437–442
  19. Jacob M, Bruegger D, Rehm M, et al. Contrasting effects of colloid and crystalloid resuscitation fluids on cardiac vascular permeability. Anesthesiology. 2006;104:1223–1231
  20. Quinlan GJ, Coudray C, Hubbard A, et al. Vanadium and copper in clinical solutions of albumin and their potential to damage protein structure. J Pharm Sci. 1992;81:611–614
  21. Nohé B, Dieterich HJ, Eichner M, et al. Certain batches of albumin solutions influence the expression of endothelial cell adhesion molecules. Intensive Care Med. 1999;25:1381–1385
  22. Boldt J, Schölhorn T, Mayer J, et al. The value of an albumin-based intravascular volume replacement strategy in elderly patients undergoing major abdominal surgery. Anesth Analg. 2006;103:191–199
  23. Heringlake M, Brückner S, Schmucker P. Different batches of human albumin solutions from one manufacturer may induce heterogenous cardiovascular effects. Intensive Care Med. 2000;26:1011–1012
  24. Bar-Or D, Bar-Or R, Rael LT, et al. Heterogeneity and oxidation status of commercial human albumin preparations in clinical use. Crit Care Med. 2005;33:1638–1641
  25. Klammt S, Brinkmann B, Mitzner S, et al. Albumin binding capacity (ABiC) is reduced in commercially available human serum albumin preparations with stabilizers. Z Gastroenterol. 2001;39(Suppl 2):24–27
  26. Olsen H, Andersen A, Nordbø A, et al. Pharmaceutical-grade albumin: Impaired drug-binding capacity in vitro. BMC Clin Pharmacol. 2004;4:4
  27. Matthes G, Seibt G, Muravsky V, et al. Albumin transport analysis of different collected and processed plasma products by electron spin resonance spectroscopy. Transfus Apher Sci. 2002;27:129–135
  28. Humpert PM, Lukic IK, Thorpe SR, et al. AGE-modified albumin containing infusion solutions boosts septicaemia and inflammation in experimental peritonitis. J Leukoc Biol. 2009;jlb.1008646v1(E-pub ahead of print)
  29. Michel CC. Starling: The formulation of his hypothesis of microvascular fluid exchange and its significance after 100 years. Exp Physiol. 1997;82:1–30
  30. Weinbaum S, Tarbell JM, Damiano ER. The structure and function of the endothelial glycocalyx layer. Annu Rev Biomed Eng. 2007;9:121–167
  31. Adamson RH, Lenz JF, Zhang X, et al. Oncotic pressures opposing filtration across non-fenestrated rat microvessels. J Physiol. 2004;557:889–907
  32. Levick JR. Revision of the Starling Principle: New views of tissue fluid balance. J Physiol. 2004;557:704
  33. Rehm M, Zahler S, Lötsch M, et al. Endothelial glycocalyx as an additional barrier determining extravasation of 6% hydroxyethyl starch or 5% albumin solutions in the coronary vascular bed. Anesthesiology. 2004;100:1211–1223
  34. Marino PL. Hemorrhage and Hypovolemia. Chapter 12 in The ICU Book (3rd ed.). Lippincott, Williams and Wilkins Philadelphia pp 222.
  35. Hillman K, Bishop G, Bristow P. The crystalloid versus colloid controversy: Present status. In:  Halkjamae H editors. Ballier's Clinical Anaesthesiology. International Practice and Research. Plasma Volume Support. 11:London: Balliere Tindall; 1997;p. 1–13
  36. Cosnett JE. The origins of intravenous fluid therapy. Lancet. 1989;768–771
  37. Shires T, Coln D, Carrico J, et al. Fluid therapy in hemorrhagic shock. Archives of Surgery. 1964;88:688–693
  38. Brandstrup B. Hemorrhage and operation cause a contraction of the extracellular space needing replacement: Evidence and implications? A systematic review. Surgery. 2006;139:419–432
  39. Hillman K. Colloids versus crystalloids in shock. Indian J Crit Care. 2004;8:14–21
  40. Brandstrup B. Fluid therapy for the surgical patient. Best Pract Res Clin Anaesthesiology. 2006;20:265–283
  41. Mann FC. Further experimental study of surgical shock. JAMA. 1918;71:1184–1188
  42. Elliott J. Preliminary report of a new method of blood transfusion. South Med Surg. 1936;98:643–645
  43. Kendrick DB. Blood program in World War Two. US Office of the Surgeon General of the Army 1964. Available at http://history.amedd.army.mil/bookdocs/wwii/blood/default.htm
  44. Schramko A, Suojaranta-Ylinen R, Kuitunen A, et al. Rapidly degradable hydroxyethyl starch solutions impair blood coagulation after cardiac surgery: A prospective randomized trial. Anesth Analg. 2009;108:30–36
  45. Stahle L, Nillson A, Hahn RG. Modelling the volume of expandable body fluid spaces during i.v. fluid therapy. Br J Anaesth. 1997;78:138–143
  46. Lobo DN, Stanga Z, Simpson JAD, et al. Dilution and redistribution effects of rapid 2-litre infusions of 0.9% (w}v) saline and 5% (w}v) dextrose on haematological parameters and serum biochemistry in normal subjects: A double-blind crossover study. Clin Sci. 2001;101:173–179
  47. Drobin D, Hahn RG. Volume kinetics of Ringer's solution in hypovolemic volunteers. Anesthesiology. 1999;90:81–91
  48. McIlroy DR, Kharasch ED. Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia. Anesth Analg. 2003;96:1572–1577
  49. Shoemaker WC. Comparison of the relative effectiveness of whole blood transfusions and various types of fluid therapy in resuscitation. Crit Care Med. 1976;4:71–78
  50. Hauser CJ, Shoemaker WC, Turpin I, et al. Oxygen transport responses to colloids and crystalloids in critically ill surgical patients. Surg Gyn Obstet. 1980;150:811–816
  51. Brinkmeyer S, Safar P, Motoyama E, et al. Superiority of colloid over electrolyte solutions for resuscitation (severe normovolemic hemodilution). Crit Care Med. 1981;9:369–370
  52. Rackow EC, Falk JL, Fein IA, et al. Fluid resuscitation in circulatory shock: A comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med. 1983;11:839–850
  53. Dawidson IJ, Willms CD, Sandor ZF, et al. Ringer's lactate with or without 3% dextran-60 as volume expanders during abdominal aortic surgery. Crit Care Med. 1991;19:36–42
  54. van der Heijden M, Verheij J, van Nieuw Amerongen P, et al. Crystalloid or colloid fluid loading and pulmonary permeability, edema, and injury in septic and nonseptic critically ill patients with hypovolemia. Crit Care Med. 2009;37:1275–1281
  55. Ernest D, Belzberg A, Dodek P. Distribution of normal saline and 5% albumin infusions in septic patients. Critl Care Med. 1999;27:46–50
  56. Modig J. Advantages of dextran 70 over Ringer acetate solution in shock treatment and in prevention of adult respiratory distress syndrome. A randomized study in man after traumatic haemorrhagic shock. Resuscitation. 1983;10:219–226
  57. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: A systematic review of randomised trials. BMJ. 1998;316:961–964
  58. Choi P, Yip G, Quinonez L, et al. Crystalloids vs. Colloids in fluid resuscitation: A systematic review. Crit Care Med. 1999;27:200–210
  59. The Albumin Reviewers , Alderson P, Bunn F, Li Wan Po A, Li L, Pearson M, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev Issue 4. 2004;Art. No. CD001208.
  60. Webb AR. Crystalloid or colloid for resuscitation. Are we any the wiser?. Crit Care. 1999;3:R25–R28
  61. Hebert P. Albumin: Should it be used in clinical practice?. On http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4096S1_08_files/frame.htmhttp://www.fda.gov/ohrms/dockets/ac/05/transcripts/2005-4096t1.htm
  62. LeLorier J, Gregoire G, Benhaddad A, et al. Discrepancies between meta-analyses and subsequent large randomized, controlled trials. N Engl J Med. 1997;337:536–542
  63. Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest. 1995;108:227S–230S
  64. Horwitz RI. Complexity and contradiction in clinical trial research. Am J Med. 1987;82:498–510
  65. Bland RD, Clarke TL, Harden LB, et al. Early albumin infusion to infants at risk for respiratory distress. Archives of Disease in Childhood. 1973;48:800–805
  66. Kanarek KS, Williams PR, Blair C. Concurrent administration of albumin with total parenteral nutrition in sick newborn infants. JPEN J Parenter Enteral Nutr. 1992;16:49–53
  67. Brown RO, Bradley JE, Bekemeyer WB, et al. Effect of albumin supplementation during parenteral nutrition on hospital morbidity. Crit Care Med. 1988;16:1177–1182
  68. Maitland K, Pamba A, English M, et al. Pre-transfusion management of children with severe malarial anaemia: A randomised controlled trial of intravascular volume expansion. Br J Haematol. 2005;128:393–400
  69. Maitland K, Pamba A, English M, et al. Randomized trial of volume expansion with albumin or saline in children with severe malaria: Preliminary evidence of albumin benefit. Clin Infect Dis. 2005;40:538–545
  70. Akech S, Gwer S, Idro R, et al. Volume expansion with albumin compared to gelofusine in children with severe malaria: Results of a controlled trial. PLoS Clin Trials. 2006;1:e21
  71. Myburgh J, Cooper J, Finfer S, et al. Saline or albumin for fluid resuscitation in patients with traumatic brain injury. N Eng J Med. 2007;357:874–884
  72. Rothwell PM. Subgroup analysis in randomized controlled trials: Importance, indications and interpretation. Lancet. 2005;365:176–186
  73. Volume Replacement With Albumin in Severe Sepsis (ALBIOS). On http://clinicaltrials.gov/ct2/show/NCT00707122
  74. Fluid resuscitation in early septic shock (PRECISE). On http://.clinicaltrials.gov/ct2/show/NCT00819416
  75. Guidet P, Mosqueda GP, Priol G, et al. The COASST study: Cost-effectiveness of albumin in severe sepsis and septic shock. J Crit Care. 2007;22:197–203
  76. Vincent JL. Hypoalbuminaemia in acute illness: Is there a rationale for intervention? A meta-analysis of cohort studies and controlled trials. Ann Surg. 2003;237:319–334
  77. Saline versus Albumin Fluid Evaluation Study Investigators. Effect of baseline serum albumin concentration on outcome of resuscitation with albumin or saline in patients in intensive care units: Analysis of data from the Saline Versus Albumin Fluid Evaluation (SAFE) study. BMJ doi: 10.1136/bmj.38985.398704.7C.
  78. Quinlan GJ, Margarson MP, Mumby S, et al. Administration of albumin to patients with sepsis syndrome: A possible beneficial role in plasma thiol repletion. Clin Sci (Lond). 1998;95:459–465
  79. Gutteridge JMC, Halliwell B. Free radicals in biology and medicine. 3rd ed.. Oxford: Oxford University Press; 1998;
  80. Quinlan GJ, Mumby S, Martin GS, et al. Albumin influences total plasma antioxidant capacity favorably in patients with acute lung injury. Crit Care Med. 2004;32:755–759
  81. Martin GS, Moss M, Wheeler AP, et al. A randomized, controlled trial of furosemide with or without albumin in hypoproteinemic patients with acute lung injury. Crit Care Med. 2005;33:1681–1687
  82. Sort P, et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med. 1999;341:403–409
  83. Chen TA, Tsao YC, Chen A, et al. Effect of intravenous albumin on endotoxin removal, cytokines, and nitric oxide production in patients with cirrhosis and spontaneous bacterial peritonitis. Scand J Gastroenterol. 2009;44:619–625
  84. Mitzner SR, Stange J, Klammt S, et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol. 2001;12(Suppl 17):S75–S82
  85. Stefoni S, Colì L, Bolondi L, et al. Molecular adsorbent recirculating system (MARS) application in liver failure: Clinical and hemodepurative results in 22 patients. Int J Artif Organs. 2006;29:207–218
  86. Laleman W, Wilmer A, Evenepoel P, et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care. 2006;10:R108
  87. Saliba F. Treatment of acute liver failure: Could MARS help?. On http://www.intensive.org/newsletter/day4.html
  88. Yap HP, Young IF, Micucci V, et al. Development of a process for the preparation of human serum albumin using chromatographic methods. Biotechnol Blood Proteins. 1993;227:143–149

 Conflict of interest: The author provides contractual services for the Plasma Protein Therapeutics Association, which represents the manufacturers of plasma products, including albumin, which operate on a profit basis.

PII: S0887-7963(09)00085-6

doi: 10.1016/j.tmrv.2009.09.005

Transfusion Medicine Reviews
Volume 24, Issue 1 , Pages 53-63 , January 2010

Article Tools

* Image Usage & Resolution